Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Efeito dos níveis de concentrado sobre as características de carcaça de ovinos Morada Nova em confinamento Effect of concentrate levels on carcass characteristics of the Morada Nova breed sheep in feedlot

Avaliaram-se as características de carcaça e os rendimentos dos cortes medidos in vivo e na carcaça de ovinos Morada Nova terminados em confinamento com dietas contendo diversos níveis de concentrado. Utilizaram-se 32 cordeiros castrados, Morada Nova, com 8,11 ± 1,15 meses de idade e peso inicial de 19,67 ± 2,97 kg, em delineamento de blocos casualizados, cada um com oito repetições. Os animais foram abatidos com 30,0 kg e alimentados com quatro níveis de concentrado (20, 40, 60 ou 80%). Houve efeito linear crescente do nível de concentrado da dieta sobre o peso do corpo vazio e peso e o rendimento da carcaça fria e efeito linear decrescente sobre o conteúdo do trato digestório e o número de dias em confinamento. Os níveis de concentrado tiveram efeito linear crescente sobre o peso e rendimento de pescoço e efeito linear decrescente sobre os rendimentos da paleta e perna, ao passo que o peso do costilhar foi influenciado de forma quadrática pelos tratamentos. Nas medidas in vivo, apenas o perímetro da perna sofreu efeito decrescente. Nas medidas na carcaça, houve efeito linear crescente sobre a largura do tórax e a compacidade, que aumentaram com o nível de concentrado na dieta, enquanto a largura da garupa teve efeito quadrático. O uso de concentrado na dieta eleva os pesos e os rendimentos de carcaça fria, mas não aumenta os pesos e rendimentos dos cortes da carcaça de cordeiros Morada Nova.<br>The in vivo carcass characteristics and the cut yields measured in the carcass of Morada Nova sheep finished in feedlot system fed increasing levels of dietary concentrate were evaluated. Thirty-two castrated Morada Nova lambs with 8.11 ± 1.15 months of age and 19.67 ± 2.97 kg of initial body weight were used in this trial. The experimet was analyzed as a completely randomized block design with eight replicates per treatment. Animals were slaughtered at 30.0 kg BW and fed diets with four concentrate levels: 20, 40, 60 or 80%. Linear increasing effect of dietary concentrate on empty body weight and cold carcass weight and yield and linear decreasing effect on digestive tract content and feedlot period were observed. The neck weight and yield linearly increased and the percentage of shoulder and leg linearly decreased with the concentrate levels, while the rib weight showed quadratic effect. In the in vivo measurements, only leg perimeter presented significant effect. There was a linear increasing effect for thoracic width and carcass compactness, while the hind width showed quadratic effect. The use of concentrate in the diet increased the weight and yields of cold carcass; however this maximization did not increase the weights and yields of commercial cuts from Morada Nova lambs